Introduction {#Sec1}
============

Mucopolysaccharidosis type VI (Maroteaux--Lamy syndrome, MPS VI, OMIM 253200) is an inherited metabolic disease caused by a deficient activity of *N*-acetylgalactosamine-4-sulfatase (4-sulfatase, arylsulfatase B, ARSB, EC 3.1.6.12), a lysosomal enzyme involved in the degradation of dermatan sulfate (DS) \[[@CR1], [@CR2]\]. The clinical presentation of MPS VI varies greatly with respect to age of onset and rate of disease progression. Descriptive classification systems have described patients' phenotypes as severe (with early onset of symptoms and fast progression), attenuated (with later onset, slower disease progression, and variable clinical presentation), and intermediate \[[@CR1], [@CR3]\]. Especially in attenuated phenotypes, a definite diagnosis may be delayed for years because early symptoms are difficult to recognize for physicians not familiar with the disease, since the disease progresses silently over decades.

The incidence rates for this rare disease vary in the literature between 0.05 \[[@CR4]\] and 2.3 \[[@CR5]\] diagnosed MPS VI patients per 100,000 live births. Allele frequencies of the different mutations are very low, and most mutations are unique to individual families, except for a high prevalence of p.R152W mutation in Eastern European population \[[@CR6]\].

This report focuses on the less severe form of MPS VI. The objective of this article is to show the existence of significant differences between so-called attenuated patients and to highlight the need of close cooperation of different specialties in order to recognize the disease early. The knowledge of natural history and genotype--phenotype correlation may also help in developing a tailored therapy.

Patients and methods {#Sec2}
====================

Patient enrollment and data collection {#Sec3}
--------------------------------------

The lists of diagnosed MPS VI patients were provided by seven diagnostic centers for MPS VI in Central and Eastern Europe (Warsaw, Prague, Vilnius, Minsk, Riga), Russia (Moscow), and Kazakhstan (Almaty). Out of these patients, only patients with the less severe form of MPS VI were included in our study.

All patients were naïve to enzyme replacement therapy (ERT) at the time of the study.

Ethical consideration {#Sec4}
---------------------

The protocol was approved by the Human Subjects Institutional Review Board at the Children's Memorial Health Institute. Written informed consent had to be provided by the parents or legal guardians. All patients and/or their families provided written consents about using their photos.

Results {#Sec5}
=======

Patient population {#Sec6}
------------------

The main demographic and clinical characteristics of all patients in our series are shown in Table [1](#Tab1){ref-type="table"}. All of the patients were Caucasian, and no sex predominance was seen. No consanguinity between parents was recorded.Table 1Clinical, biochemical, and molecular data of MPS VI patients heterozygous for p.Y210C mutationCase number (country, current age)Age at onset of symptoms/age at diagnosis (years)Symptoms at onsetOther symptoms before MPS VI diagnosisMisdiagnosis/initial diagnosisExtraskeletal involvement during the disease courseARSB activity^a^Genotype^b^1 (Czech Republic, 47)10/45DW, HP, JS, RRCFF, GR, SKHip dysplasia, Perthes diseaseCH, IH, M, SCC, UH, HC10.8p.R160X/p.Y210C2 (Russia, 40)8/38JSDW, HP, HC, SCCChondrodysplasia, osteochondrosisCFF, HC, SCC7.4p.Y210C/p.C521Y3 (Belarus, 36)8/9JSNoHip dysplasiaCFF, DW, HP, CFF, RR9.8p.T92K/p.Y210C4 (Russia, 20)5/10JS, RR, IHNoNoCFF, HC9.8p.N262Kfs\*14/p.Y210C*DW* difficulty in walking, *CFF* coarse facial features, *CH* claw hands, *GR* growth retardation, *HC* hydrocephalus, *HP* hip pain, *IH* impaired hearing, *JS* joint stiffness, *M* myelopathy, *RR* recurrent rhinitis, *SCC* spinal cord compression, *SK* skeletal abnormalities, *UH* umbilical hernia^a^ARSB activity in the patients' leukocytes was referred to the mean value of several controls analyzed in the same experiment^b^NCBI reference sequence: NM_000046.3 (cDNA considering A of the ATG translation initiation codon as nucleotide +1); NP_000037

### First clinical features and disease progression {#Sec7}

For all four patients, the age of first symptom onset ranged from 5 to 8 years (median 8 years). The most common first sign to appear was decreased joint range of motion of large joints of the upper and/or lower limbs. The most commonly affected joints were hips, which resulted in hip pain with difficulty in walking and stair climbing. The first misdiagnoses in these patients were Perthes disease, hip dysplasia or osteochondrosis. In addition to the joint problems, some of the patient cohort reported features such as recurrent rhinitis, impaired hearing, hydrocephalus, and in the case of older patients, spinal cord compression.

Within the disease course, the patients developed other disease manifestations such as skeletal abnormalities (Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}), growth retardation, and spinal cord compression.Fig. 1**a**, **b** Radiographs of a patient heterozygous for the p.Y210C mutation. Lateral radiographs of cervical spine: (1) reduction of cervical lordosis, (2) narrowing of L3 vertebral body and dislocation of L4 vertebral body (*arrows*), and (3) thickening of the skull bonesFig. 2Pictures of MPS VI patients heterozygous for the p.Y210C mutation

Joint stiffness was reported in all patients. It was located mainly in the shoulder and hip joints or other large joints of the upper and/or lower limbs. It was intense and significantly impaired the quality of the patient's life leading to consultations by orthopedic surgeons. Typical for MPS contractures of fingers (so-called claw hands) were also observed decreasing the function, efficiency, and skills of the hands.

At the time of the study, the eldest patients were 45 and 40 years of age.

### Delayed diagnosis {#Sec8}

Following the onset of signs and symptoms, MPS VI diagnosis occurred after 9 years of age (range 9--45 years, median 24 years) with median delays 17.5 years.

Literature review {#Sec9}
-----------------

### Clinical phenotypes {#Sec10}

The results of the literature review are presented in Table [2](#Tab2){ref-type="table"}, which includes only reports with clinical data (*n* = 36). The review of the literature allowed distinguishing two types of attenuated MPS VI phenotypes: osteoarticular and cardiac.Table 2Literature review of patients with an attenuated phenotype of mucopolysaccharidosis type VICase number (country)Age at onset of symptoms/age at diagnosis (years)Symptoms at onsetClinical manifestations during disease courseMisdiagnosis/initial diagnosisGenotypeRef.1nd**HP**CC, SK, VDPerthes diseasendMcKusick \[[@CR15]\]2 (Germany)7/40**SK**, TS (mild)CC, CFF, CM, JS, SK, VDPerthes diseasendPilz et al. \[[@CR25]\]3 (Germany)10/38**JD**CC, CFF, CM, JS, SK, VDndndPilz et al. \[[@CR25]\]4 (New Zealand)nd/13**FP**CC, IH, SK, VDndndPaterson et al. \[[@CR26]\]5 (New Zealand)nd/16ndCC, GR, IH, JS, SK, VDndndPaterson et al. \[[@CR26]\]6 (Denmark)6/27**HP**, **WG**HD, RMndndTonnesen et al. \[[@CR27]\]7 (New Zealand?)4/9GR, CCCFFndC192R/C192RIsbrandt et al. \[[@CR9]\]8 (nd)nd/11ndCC, CFF, GR, IH, JSndY210C/-Litjens et al. \[[@CR28]\]9 (nd)nd/13ndGR, IH, SK, VDndR95Q/Y210CLitjens et al. \[[@CR28]\]10 (nd)nd/16ndndndR95Q/Y210CLitjens et al. \[[@CR28]\]11 (nd)nd/15ndCC, GR, H, JS, SKndY210C/-Litjens et al. \[[@CR28]\]12 (nd)nd/17ndndH393P/-Litjens et al. \[[@CR28]\]13 (nd)nd/35ndndT92M/L498PLitjens et al. \[[@CR28]\]14 (Denmark)nd/44ndHA, PP, DL, H, IH, JSndP313A/P481LBrooks et al. \[[@CR29]\]15 (Italy)7/35**SK**, **JP**, **JS**CC, CFF, CTS, GR, JS, SK, VDCarpal tunnel syndromeY210C/G302RScarpa et al. \[[@CR30]\]16 (Italy)nd/38**HD**, CH, RRCC, CFF, JS, SK, VDSuspected endocrine/rheumatologic disorderY210C/G302RScarpa et al. \[[@CR30]\]17 (Ireland)2/16**BP**, **HP**JPndY210C/Y210CGottwald et al. \[[@CR11]\]18 (Germany)11/29**SK**, CC, GR, RIRA, VD, JP, SK, SCC, CC, GR, CM, IVndR152W/Q104HThümler et al. \[[@CR31]\]19 (Germany)14/25**SK**, HCCC, JC, VD, RA, RM, SKndR152W/R152W20 (Germany)10/25RI, IHJC, VD, JP, RM, SCCndR160X/Y210C21 (Germany)12/22**HP**, **BP**, **SK**VD, CTS, RM, SCC, SKndR160X/Y210C22 (Turkey)6/19**HD**/**JP**, **RM**, **SK**, CCIV, VA, CCO, RA, CC, SCC, SKndC192R/C192R23 (Germany)11/24**WG**, **HD**, **SK**SK, JP, CC, CTS, VD, CCO, SKndY210C/W146X24 (Germany)20/28**HD**, **JC**, **CH**, RI, RHCFF, RM, CC, VD, SK, JSndY210C/?25 (Germany)12/20**HD**, **JC**, **CH**, RICFF, CC, VD, SK, JSndY210C/?26 (Germany)18/25**HD**, **JC**, **CH**, RI, VDCFF, CC, VD, SK, JSndY210C/?27 (Poland)21/37**VD**, JS (mild)CC, CFF, GR, JS, SKRheumatic heart diseaseR152W/R152WJurecka et al. \[[@CR8]\]28 (Lithuania)7/30**VD**, GR (mild)CFF, GR, HC, IH, MC, JS, SCC, SKRheumatic heart diseaseR152W/R152W29 (Belarus)15/22**VD**, GR (mild), CC (mild)CC, CTS, GR, H, JS, SKChronic cardiac insufficiencyR152W/R152W30 (Belarus)15/22**VD**, JS (mild), GR (mild), CC (mild)CC, CFF, CTS, GR, H, JS, SKChronic cardiac insufficiencyR152W/R152W31 (Russia)17/26**VD**, AGS (mild)CFF, JS, GR, MC, SCC, SKChronic cardiac insufficiencyR152W/R152W32 (Russia)18/20**VD**, HI, JS (mild)CFF, GR, MC, SKChronic cardiac insufficiencyR152W/R152W33 (Lithuania)15/23**VD**, GR (mild)CFF, GR, IH, MC, JS, SKRheumatic heart diseaseR152W/R152W34 (Russia)5/24**VD**, HI, CC (mild), GRGR, CC, HS, JS, SKChronic cardiac insufficiencyR152W/R152W35 (Lithuania)6/15**VD**, AGS (mild), JS (mild)CFF, GR, HC, JS, MC, SKndR152W/R152W36 (Belarus)5/13**VD**, AGS (mild)CTS, GR, JS, MC, RR, SKndR152W/R152W*nd* no data, *BP* back pain, *CC* corneal clouding, *CCO* cardiac complications, *CH* claw hands, *CFF* coarse facial features, *CM* cervical myelopathy, *CTS* carpal tunnel syndrome, *DL* dyslexia, *FP* foot pain, *AGS* abnormal gait stereotype, *GR* growth retardation, *H* hepatomegaly, *HA* halitosis, *HC* hydrocephalus, *HD* hip dysplasia, *HI* inguinal hernia, *HP* hip pain, *HS* hepatosplenomegaly, *IH* impaired hearing, *IV* impaired vision, *MC* macrocephaly, *JC* joint contractures, *JD* joint dysfunction, *JS* joint stiffness, *JP* joint pain, *PP* photophobia, *RA* respiratory abnormalities, *RH* recurrent hernia, *RI* recurrent infections, *RM* reduced mobility, *RR* recurrent rhinitis, *SCC* spinal cord compression, *SK* skeletal abnormalities, *TS* tetraspasticity, *VD* valve disease, *WG* waddling gait

In a majority of reported patients, a relatively attenuated phenotype meant an essentially osteoarticular phenotype. These patients initially presented with bone and joint symptoms, especially pain and stiffness in the joints, joint contractures, and hip and back pain. At some point, most of these patients developed serious manifestations of the disease including joint degeneration, sleep apnea, a decrease in pulmonary function, reduced endurance, cardiac valve disease, and skeletal complications including carpal tunnel syndrome and hip disease.

Unlike the majority of reviewed patients, patients homozygous for p.R152W mutation showed a significantly different clinical phenotype with predominance of cardiovascular manifestations \[[@CR7], [@CR8]\].

### Genotype--phenotype correlation {#Sec11}

Mutations associated with an attenuated MPS VI phenotype are presented in Table [3](#Tab3){ref-type="table"}.Table 3Characteristics of the changes in the *ARSB* gene associated with an attenuated MPS VI phenotypeLocationChange at DNA level^a^Predicted effect on amino acid sequence of the proteinType of mutationReferenceEx. 1c.247G\>Cp.D83YMissenseKarageorgos et al. \[[@CR10]\]Ex. 2c.454C\>Tp.R152WMissenseVoskoboeva et al. \[[@CR32]\]Ex. 3c.574T\>Cp.C192RMissenseIsbrandt et al. \[[@CR9]\]c.629A\>Gp.Y210CMissenseLitjens et al. \[[@CR4]\]Ex. 7c.1214G\>Ap.C405YMissenseKarageorgos et al. \[[@CR10]\]c.1301G\>Tp.R434IMissenseKarageorgos et al. \[[@CR10]\]*Ex* exon^a^NCBI reference sequence: NM_000046.3 (cDNA considering A of the ATG translation initiation codon as nucleotide +1)

Apart from the p.R152W and p.Y210C mutations, other mutations have been reported as associated with attenuated disease progression: p.C192R \[[@CR9]\] when present in homozygous state and p.D83Y \[[@CR10]\], p.C405Y \[[@CR10]\], and p.R434I \[[@CR10]\] when present in compound heterozygous states. Osteoarticular attenuated phenotype is predominantly associated with a missense mutation p.Y210C, while cardiac with p.R152W in homozygosity. So far, only one patient homozygous for p.Y210C mutation has been described in the literature, while in the majority of patients, this mutation is present with other mis- or nonsense mutation \[[@CR11]\].

Discussion {#Sec12}
==========

One of the first descriptions of mucopolysaccharidosis type VI was probably by the neurologist Nonne \[[@CR12]\]. After several investigators indicated heterogeneity of MPS VI based on radiological findings, the patients' size, and longevity \[[@CR13], [@CR14]\], McKusick suggested separating a severe form (mucopolysaccharidosis type VIA) from a mild variant (type VIB) \[[@CR15]\]. Based on McKusick's classification, the longevity, size, lack of cardiac insufficiency in association with mild cardiac murmurs, lack of abnormality of sella turcica, and the absence of umbilical or inguinal hernia, marked hepatosplenomegaly, and marked corneal opacities warranted the diagnosis of the mild B variant of MPS VI \[[@CR15]\]. Apart from severe and attenuated phenotypes, descriptive classification systems have also described an intermediate disease form. Other authors suggested other classification systems based on height and urinary glycosaminoglycan (uGAG) levels, the age at the onset of symptoms, patient's height, and the age of death \[[@CR16], [@CR17]\]. In reality, there are no fixed parameters to ascribe a particular patient to a single category, and the decision is subjective depending on physician's experience and knowledge. The relatively attenuated disease form is generally characterized by later onset of symptoms which may not at first appear in a recognized pattern, but when apparent, the milder symptoms may be observed by an alert physician and lead ultimately to diagnosis usually after 5 years of age, but it may be delayed until the second or third decades.

Results from our study and review of the literature allow for distinguishing two types of attenuated MPS VI phenotypes: osteoarticular and cardiac. It is likely that patients with osteoarticular symptoms will be found in either rheumatology or orthopedic clinics. The similarity of attenuated MPS VI to the more commonly seen rheumatological conditions means that patients are often misdiagnosed and there is a delay before the patient's symptoms are attributed to MPS. Patients with a cardiac variant of MPS VI are much more probable to be found in cardiology clinics \[[@CR18], [@CR19]\]. In these patients, cardiac disease progresses silently and ultimately leading to heart failure and does not correspond with the other typical MPS features which are very mild or absent \[[@CR8]\]. An advanced valve defect is an indication for valve surgery, which may be beneficial in these patients at an earlier stage of the disease. In both phenotypes, the pathological process seems to be restricted at first to one system only, either osteoarticular or cardiovascular. In the cardiac phenotype, however, it tends to have more serious complications leading to fast disease progression and abrupt death \[[@CR7]\].

Despite the utility of communicating with these descriptive categories, it is important to recognize that the symptoms of the disease manifested along a continuum. Using a descriptive classification is very helpful for clinicians; however, it is important to bear in mind its implications. The term attenuated (or used by some slowly progressing) implies a slower disease progression, and it may be perceived that these patients do not require treatment as urgently as severe patients. The truth is that these patients may remain asymptomatic for years with silently (but not necessarily slowly) progressing disease and be recognized in an advanced disease stage when it is too late for any intervention \[[@CR7]\]. For this reason, we previously suggested using a term *cardiac MPS VI variant* to add a sense of urgency as these patients require treatment to be administered prior to the onset of valve disease \[[@CR8]\].

The awareness among cardiologists and rheumatologists should be raised so they can play an important role, not only in the management but also in the diagnosis of these patients \[[@CR18]\]. The extent of cardiac involvement may be underestimated in patients with mucopolysaccharidosis because of restrictive pulmonary disease and skeletal abnormalities that limit patients' activities \[[@CR19]\]. We have previously presented a diagnostic algorithm, suggesting uGAG analysis in any patient with valve disease even in the presence of very mild or untypical disease symptoms \[[@CR18]\]. In cases with a high index of suspicion such as those with a positive family history or those with other characteristic features of MPS VI, enzymatic activity should be determined even if uGAG excretion is low. As attenuated patients may still be very difficult to recognize, the delay in diagnosis may make it difficult to influence valve disease with available treatment. Apart from this, we have to bear in mind that the usefulness of enzyme replacement therapy is limited due to the fact that a given enzyme preparation does not have beneficial effects on all aspects of a disorder in the same degree. The effect of ERT alone on cardiac structure and function in MPS patients has been documented in only a few studies \[[@CR20]--[@CR23]\] and larger studies with longer follow-up are still needed. Additionally, clinical studies have shown that many symptoms of mucopolysaccharidoses even after long-term treatment are not anymore reversible. It seems probable that in the future, a tailored combination therapy using ERT with novel therapeutic options such as application of small molecules that either inhibit a key enzyme which is responsible for substrate synthesis (substrate deprivation) or act as a chaperone to increase the residual activity of the lysosomal enzyme (enzyme-enhancing therapy) will be the most effective \[[@CR24]\].

By identifying patient's genotype, it may be possible to predict the course of the disease and establish more tailored treatment plan. Patients with the p.Y210C mutation should be covered by a special care team of orthopedists, physiotherapists, and rheumatologists with a plan of rehabilitation, proper early use of orthoses and other support devices, the best determination of time for bone and joint surgery, and application of drug treatments. Patients with the p.R152W should be referred to a cardiologist before the appearance of symptoms from the circulatory system. The mechanism why the p.R152W mutation seems to have a special affinity for the heart valves remains unknown. Perhaps this stems from the specific structure of the valves, and each of these mutations causes different residual enzyme activity. Detecting these differences would explain the process of affecting different organs dependent on the flow dynamics of the substrate.

Conclusions {#Sec13}
===========

Based on the literature review, two types of attenuated MPS VI phenotypes can be distinguished: osteoarticular and cardiac, both with a clear genotype--phenotype correlation.The majority of MPS VI patients reported so far as relatively attenuated presented with an essentially osteoarticular phenotype associated with p.Y210C mutation in heterozygosity.The term attenuated should be used with caution as it may imply the slow disease progression and the lack of urgency to treat these patients.
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